Sanofi SA has become the latest pharma company to wind down its interest in consumer healthcare in order to focus on proprietary, prescription medicines. The French company is to sell a 50% controlling stake in Opella, its consumer business, to the US private equity group Clayton Dubilier & Rice. Under the deal, Sanofi will retain a significant interest in Opella, while increasing investment in new biopharma products and vaccines, according to Paul Hudson, the chief executive.
